Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma

Antiangiogenic therapy resistance occurs frequently in patients with metastatic renal cell carcinoma (RCC). The purpose of this study was to understand the mechanism of resistance to sunitinib, an antiangiogenic small molecule, and to exploit this mechanism therapeutically. We hypothesized that suni...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncogene
Autori principali: Zhou, Lijun, Liu, Xian-De, Sun, Mianen, Zhang, Xuesong, German, Peter, Bai, Shanshan, Ding, Zhiyong, Tannir, Nizar, Wood, Christopher G, Matin, Surena F, Karam, Jose A, Tamboli, Pheroze, Sircar, Kanishka, Rao, Priya, Rankin, Erinn B., Laird, Douglas A, Hoang, Anh G, Walker, Cheryl L, Giaccia, Amato J, Jonasch, Eric
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2015
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4791213/
https://ncbi.nlm.nih.gov/pubmed/26364599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2015.343
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi